APOE4 also renders the cerebrovasculature fragile to the point where the only disease-modifying AD therapeutic, anti-amyloid monoclonal antibodies, are warned against use in APOE4 carriers due to a high risk of hemorrhage and edema. This evidence concerns the gene APOE and Alzheimer disease.